Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to
abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating …

Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …

Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-
cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …

Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are …

Background The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide
and dexamethasone has been shown to be effective in patients with relapsed or refractory …

Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven
efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M …